Market positioning Focus on Aviva Systems Biology as a mid-sized biotech supplier with a broad catalog of antibodies, ELISAs, and proteins, complemented by custom recombinant antibody discovery and assay development. This presents opportunities to upsell advanced custom services to customers moving toward translational research and diagnostic workflows.

Expansion signals Recent launches and partnerships indicate a growth trajectory in recombinant antibodies, anti-progranulin clones, and semi-custom protein offerings. Target potential clients in neurology, inflammation, and biomarker assay development who could benefit from expanding to Recombinant antibodies and Proteins on Demand.

Global reach Headquartered in San Diego with distributors worldwide suggests a broad customer base and channel partners to leverage for multi-region sales, regional KOL engagements, and distributor-led campaigns to accelerate adoption of new recombinants and diagnostic workflows.

Product breadth Diverse product line including AvivaBlot ECL reagents and new recombinant protein capabilities provides cross-sell opportunities to labs upgrading assay repertoires, enabling bundled offerings for western blot, immunoassays, and biomarker verification in preclinical and translational studies.

Market fit Revenue scale and target markets align with life science segments seeking validated reagents and assay-ready resources. Prioritize outreach to neuroscience, cancer, and immunology investigators pursuing target validation, biomarker panels, and assay development to de-risk early-stage programs.